Absci Investor Presentation Deck

CASE STUDY: MULTIPLE INSERTIONS OF NON-STANDARD AMINO ACIDS Increased drug to antibody ratio with the incorporation of multiple nsAAs We investigated our ability to produce bionic Trastuzumab with 1, 2, or 3 nsAA incorporation sites H289 1257 A166 A122 *DAR = Drug-to-Antibody Ratio ABSCI CORPORATION 2023 ALL RIGHTS RESERVED 1x nsAA = DAR 2 2x nsAAS = DAR 4 3x nsAAs = DAR 6 Relative expression II 2 x nsAA O nsAA (wt) OOOO OOOO OOOO 1 x nsAA 3 x nsAA 3 x nsAA (alt) O OOOO Bionic SoluPro™ has been able to incorporate a non- standard amino acid into a total of 3 sites of a heavy chain mAb without major reductions in titer absci. 38

View entire presentation